Kymera Therapeutics Inc - KYMR Quarterly EPS earnings growth

Corporate company logo of Kymera (KYMR)

The foundation of Kymera Therapeutics (KYMR) growth is its authority in developing protein degradation systems to combat cancer. The quarterly EPS growth rate confirms this status, with the parameter value reaching -39.40. Efficiency is supported by the implementation of sustainable laboratory standards and operations within a closed biotech ecosystem, whose success in oncology depends on FDA approval and advances from major pharma partners.

kymeratx.com (KYMR) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/18/2026

Analytical breakdowns for Kymera Therapeutics

- share price and consensus valuation forecast:
Fundamental company valuation:kymeratx.com - KYMR
Flagship merchandise of kymeratx.com

Quarterly EPS growth measures the percentage change in net income per share over a rolling period. Professionals utilize this rate to assess business scaling efficiency and cost management. By analyzing the intensity of quarterly EPS growth, an investor determines the sustainability of the financial result. For Kymera Therapeutics (KYMR), this trend is critical due to clinical trial expenses. The risks of therapy development failures could instantaneously wipe out the positive momentum of this metric.

Analysis of competing companies

GMAB (Genmab) - Year-over-year net earnings per share growth for the last 12 months|EXEL: Year-over-year earnings per share growth rate for the last twelve months|NUVL (Nuvalent Therapeutics) - Quarterly EPS earnings growth|Quarterly EPS earnings growth ideayabio.com|Year-over-year earnings per share growth for the last twelve months Enliven Therapeutics, Inc. (ELVN)|ORIC (ORIC Pharmaceuticals, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth RLAY (Relay Therapeutics Inc)|Net earnings per share growth for the trailing year Nurix Pharma|Tyra Biosciences Inc - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Verastem|GLUE (Monte Rosa Therapeutics) - Year-over-year net earnings per share growth for the last 12 months|CGEM: Year-over-year earnings per share growth rate for the last twelve months|IMRX (immuneering.com) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months C4 Tx CCCC|Quarterly EPS earnings growth BDTX|Repare Therapeutics Inc. - Year-over-year earnings per share growth for the last 12 months|PMV Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months KPTI|PPCB: Year-over-year net earnings per share growth for the last 12 months|Cyclacel Pharmaceuticals - Year-over-year earnings per share growth rate for the last twelve months|AADI: Quarterly EPS earnings growth|Aileron Therapeutics Inc - Year-over-year earnings per one share growth for the last 12 months|BPMC (Blueprint Medicines Corp.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months glycomimetics.com GLYC|Year-over-year earnings per share growth for the last twelve months SpringWorks (SWTX)